Lantheus Holdings, Inc. (LNTH)
LNTH Stock Price Chart
Explore Lantheus Holdings, Inc. interactive price chart. Choose custom timeframes to analyze LNTH price movements and trends.
LNTH Company Profile
Discover essential business fundamentals and corporate details for Lantheus Holdings, Inc. (LNTH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Jun 2015
Employees
808.00
Website
https://www.lantheus.comCEO
Brian A. Markison
Description
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
LNTH Financial Timeline
Browse a chronological timeline of Lantheus Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is $1.33.
Earnings released on 6 Aug 2025
EPS came in at $1.57 falling short of the estimated $1.64 by -4.27%, while revenue for the quarter reached $378.05M , beating expectations by +4.25%.
Earnings released on 7 May 2025
EPS came in at $1.53 falling short of the estimated $1.68 by -8.93%, while revenue for the quarter reached $372.76M , missing expectations by -5.69%.
Earnings released on 26 Feb 2025
EPS came in at $1.59 surpassing the estimated $1.58 by +0.63%, while revenue for the quarter reached $391.11M , beating expectations by +3.07%.
Earnings released on 6 Nov 2024
EPS came in at $1.70 surpassing the estimated $1.56 by +8.97%, while revenue for the quarter reached $378.73M , beating expectations by +0.77%.
Earnings released on 31 Jul 2024
EPS came in at $1.80 falling short of the estimated $1.83 by -1.64%, while revenue for the quarter reached $394.09M , beating expectations by +3.12%.
Earnings released on 2 May 2024
EPS came in at $1.69 surpassing the estimated $1.54 by +9.74%, while revenue for the quarter reached $369.98M , missing expectations by -3.19%.
Earnings released on 22 Feb 2024
EPS came in at $1.75 surpassing the estimated $1.45 by +20.69%, while revenue for the quarter reached $354.00M , beating expectations by +3.41%.
Earnings released on 2 Nov 2023
EPS came in at $1.47 surpassing the estimated $1.32 by +11.36%, while revenue for the quarter reached $319.95M , beating expectations by +1.80%.
Earnings released on 3 Aug 2023
EPS came in at $1.54 surpassing the estimated $1.31 by +17.56%, while revenue for the quarter reached $321.70M , beating expectations by +5.22%.
Earnings released on 4 May 2023
EPS came in at $1.47 surpassing the estimated $1.29 by +13.95%, while revenue for the quarter reached $300.78M , beating expectations by +7.18%.
Earnings released on 23 Feb 2023
EPS came in at $1.37 surpassing the estimated $0.96 by +42.71%, while revenue for the quarter reached $263.17M , beating expectations by +7.53%.
Earnings released on 3 Nov 2022
EPS came in at $0.99 surpassing the estimated $0.83 by +19.28%, while revenue for the quarter reached $239.29M , beating expectations by +4.95%.
Earnings released on 4 Aug 2022
EPS came in at $0.89 surpassing the estimated $0.70 by +27.14%, while revenue for the quarter reached $223.72M , beating expectations by +9.45%.
Earnings released on 29 Apr 2022
EPS came in at $0.97 surpassing the estimated $0.46 by +110.87%, while revenue for the quarter reached $208.88M , beating expectations by +26.36%.
Earnings released on 24 Feb 2022
EPS came in at $0.25 surpassing the estimated $0.17 by +47.06%, while revenue for the quarter reached $129.56M , beating expectations by +15.91%.
Earnings released on 4 Nov 2021
EPS came in at $0.08 surpassing the estimated $0.06 by +33.33%, while revenue for the quarter reached $102.07M , beating expectations by +5.09%.
Earnings released on 28 Jul 2021
EPS came in at $0.11 surpassing the estimated $0.05 by +120.00%, while revenue for the quarter reached $101.06M , beating expectations by +34.68%.
Earnings released on 4 May 2021
EPS came in at $0.05 surpassing the estimated $0.01 by +576.59%, while revenue for the quarter reached $92.51M , missing expectations by -84.13%.
Earnings released on 25 Feb 2021
EPS came in at $0.07 surpassing the estimated $0.01 by +483.33%, while revenue for the quarter reached $94.15M , missing expectations by -77.78%.
Earnings released on 5 Nov 2020
EPS came in at $0.04 surpassing the estimated $0.01 by +332.43%, while revenue for the quarter reached $88.54M , beating expectations by +300.00%.
LNTH Stock Performance
Access detailed LNTH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.